Proteolix raises $79 million for proteasome inhibitor development
This article was originally published in Scrip
Executive Summary
Proteolix has secured $79 million in a series C financing round to fund the clinical development of its anticancer carfilzomib and its pipeline of proteasome inhibitors. The US company plans to complete ongoing Phase II studies of the anticancer before advancing its development further.